{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:21:58Z","timestamp":1793827318828,"version":"4.6.1"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"\n Importance<\/jats:title>\n Stimulants are increasingly prescribed for US adults. Whether such prescribing is associated with misuse and prescription stimulant use disorder (PSUD) is less understood.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n \n To examine (1) sex- and age-specific trends in the number of persons dispensed stimulants and trends in dispensed prescription stimulants by prescriber specialty in 2019 through 2022; (2) prevalence of misuse and PSUD by use of prescription amphetamine-type stimulants (hereafter referred to as\n amphetamines<\/jats:italic>\n ) and methylphenidate; and (3) PSUD prevalence and sociodemographic and behavioral health correlates among persons using prescription stimulants with and without prescription stimulant misuse.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional survey study used the 2019-2022 IQVIA Total Patient Tracker and National Prescription Audit New to Brand databases and the 2021-2022 National Surveys on Drug Use and Health (NSDUH) (community-dwelling 18- to 64-year-old individuals). Data analysis was performed from March to April 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Past-year use of prescription stimulants.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n PSUD using\n DSM-5<\/jats:italic>\n criteria.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the sampled 83\u202f762 adults aged 18 to 64 years, 33.8% (unweighted) were aged 18 to 25 years, 53.0% (unweighted) were aged 26 to 49 years, and 56.0% (unweighted) were women. Among those using prescription stimulants, 25.3% (95% CI, 23.8%-26.8%) reported misuse, and 9.0% (95% CI, 8.0%-10.0%) had PSUD. Among those with PSUD, 72.9% (95% CI, 68.3%-77.6%) solely used their own prescribed stimulants, 87.1% (95% CI, 82.3%-90.8%) used amphetamines, 42.5% (95% CI, 36.6%-48.5%) reported no misuse, and 63.6% (95% CI, 56.8%-69.8%) had mild PSUD. Individuals using amphetamines, compared with those using methylphenidate, had higher prevalence ratios of misuse (3.1 [95% CI, 2.2-4.3]) and PSUD (2.2 [95% CI, 1.3-3.8]). The largest increase in the number of individuals dispensed prescription stimulants was among women aged 35 to 64 years, from 1.2 million in quarter 1 of 2019 to 1.7 million in quarter 4 of 2022 (average quarterly percentage change, 2.6% [95% CI, 2.1%-3.1%]). The prevalence of prescription stimulant misuse was lower among women aged 35 to 64 years using these medications (13.7% [95% CI, 11.1%-16.8%]) than other sex- and age-specific subgroups (ranging from 22.0% [95% CI, 17.9%-26.7%] for men aged 35-64 years to 36.8% [95% CI, 32.6%-41.2%] for women aged 18-25 years).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n High prevalence of prescription stimulant misuse and PSUD (regardless of misuse status) suggests the importance of ensuring clinically appropriate use and of screening for and treating PSUD among all adults prescribed stimulants, especially those using amphetamines. Findings may suggest potential progress in addressing the mental health care gap for middle-aged women and the need for evidence-based clinical guidance and training on benefits and risks of prescription stimulants for adults.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2025.0054","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:37:58Z","timestamp":1742384278000},"page":"572","source":"Crossref","is-referenced-by-count":48,"title":["Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years"],"prefix":"10.1001","volume":"82","author":[{"given":"Beth","family":"Han","sequence":"first","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora D.","family":"Volkow","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Michaela","family":"Rikard","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Dowell","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Einstein","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gery P.","family":"Guy","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Tomoyasu","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Ko","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvild","family":"Olsen","sequence":"additional","affiliation":[{"name":"Substance Abuse and Mental Health Services Administration, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson M.","family":"Compton","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"yoi250004r1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamapsychiatry.2023.5045","article-title":"Trends in incident prescriptions for behavioral health medications in the US, 2018-2022.","volume":"81","author":"Chai","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"yoi250004r2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpsychires.2020.01.006","article-title":"A literature review and meta-analysis on the effects of ADHD medications on functional outcomes.","volume":"123","author":"Boland","year":"2020","journal-title":"J Psychiatr Res"},{"issue":"10","key":"yoi250004r3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jama.2024.0851","article-title":"ADHD pharmacotherapy and mortality in individuals with ADHD.","volume":"331","author":"Li","year":"2024","journal-title":"JAMA"},{"issue":"13","key":"yoi250004r4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.15585\/mmwr.mm7213a1","article-title":"Trends in stimulant prescription fills among commercially insured children and adults\u2014United States, 2016-2021.","volume":"72","author":"Danielson","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"yoi250004r6","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1017\/S0033291723002544","article-title":"Elemental psychopathology: distilling constituent symptoms and patterns of repetition in the diagnostic criteria of the DSM-5.","volume":"54","author":"Forbes","year":"2024","journal-title":"Psychol Med"},{"issue":"12","key":"yoi250004r7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/10870547231177470","article-title":"The ability of self-report methods to accurately diagnose attention deficit hyperactivity disorder: a systematic review.","volume":"27","author":"Harrison","year":"2023","journal-title":"J Atten Disord"},{"issue":"12","key":"yoi250004r8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11920-020-01194-9","article-title":"Screening for adult ADHD.","volume":"22","author":"Anbarasan","year":"2020","journal-title":"Curr Psychiatry Rep"},{"issue":"7","key":"yoi250004r9","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.mayocp.2022.02.026","article-title":"Attention-deficit\/hyperactivity disorder overdiagnosis and overprescriptions: medicalization of distractions.","volume":"97","author":"Moustafa","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"yoi250004r10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1176\/appi.ajp.20230329","article-title":"Risk of incident psychosis and mania with prescription amphetamines.","volume":"181","author":"Moran","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi250004r11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/10550887.2020.1732762","article-title":"Prevalence of ADHD symptom malingering, nonmedical use, and drug diversion among college-enrolled adults with a prescription for stimulant medications.","volume":"38","author":"Ramachandran","year":"2020","journal-title":"J Addict Dis"},{"issue":"8","key":"yoi250004r12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1176\/appi.ajp.2018.17091048","article-title":"Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States.","volume":"175","author":"Compton","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"8","key":"yoi250004r13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3949\/ccjm.82a.14131","article-title":"Universal precautions to reduce stimulant misuse in treating adult ADHD.","volume":"82","author":"Modesto-Lowe","year":"2015","journal-title":"Cleve Clin J Med"},{"issue":"8","key":"yoi250004r15","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: recommendations and rationale.","volume":"170","author":"Hasin","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"9","key":"yoi250004r16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/10826084.2023.2212037","article-title":"Receipt of prescription psychostimulants and stimulant-involved fatal overdose: a population-based case-control study.","volume":"58","author":"Macmadu","year":"2023","journal-title":"Subst Use Misuse"},{"issue":"5","key":"yoi250004r17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/add.14122","article-title":"Risk of amphetamine use disorder and mortality among incident users of prescribed stimulant medications in the Veterans Administration.","volume":"113","author":"Westover","year":"2018","journal-title":"Addiction"},{"issue":"40","key":"yoi250004r18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.15585\/mmwr.mm7340a1","article-title":"Attention-deficit\/hyperactivity disorder diagnosis, treatment, and telehealth use in adults\u2014National Center for Health Statistics Rapid Surveys System, United States, October-November 2023.","volume":"73","author":"Staley","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"35","key":"yoi250004r19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.15585\/mmwr.mm7235a3","article-title":"Drug overdose deaths with evidence of counterfeit pill use\u2014United States, July 2019-December 2021.","volume":"72","author":"O\u2019Donnell","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"yoi250004r27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/aje\/kwp440","article-title":"Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data.","volume":"171","author":"Bieler","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"4","key":"yoi250004r28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/syn.20235","article-title":"Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine.","volume":"59","author":"Schiffer","year":"2006","journal-title":"Synapse"},{"issue":"1","key":"yoi250004r29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1087054719859081","article-title":"Telemedicine in the management of ADHD: literature review of telemedicine in ADHD.","volume":"24","author":"Spencer","year":"2020","journal-title":"J Atten Disord"},{"issue":"20","key":"yoi250004r32","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMcp1212625","article-title":"Clinical practice: adult attention deficit-hyperactivity disorder.","volume":"369","author":"Volkow","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"yoi250004r33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.encep.2019.06.005","article-title":"Practical considerations for the evaluation and management of attention deficit hyperactivity disorder (ADHD) in adults.","volume":"46","author":"Weibel","year":"2020","journal-title":"Encephale"},{"issue":"1","key":"yoi250004r34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.acap.2019.06.002","article-title":"Stimulant diversion risk among college students treated for ADHD: primary care provider prevention training.","volume":"20","author":"Molina","year":"2020","journal-title":"Acad Pediatr"},{"issue":"8","key":"yoi250004r35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1176\/appi.ajp.2018.18050596","article-title":"Prescription stimulant use and misuse: implications for responsible prescribing practices.","volume":"175","author":"Arria","year":"2018","journal-title":"Am J Psychiatry"},{"key":"yoi250004r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105703","article-title":"The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis.","volume":"162","author":"Isfandnia","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"yoi250004r37","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/jamapsychiatry.2023.4294","article-title":"Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases.","volume":"81","author":"Zhang","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi250004r38","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1186\/s12889-023-16256-9","article-title":"Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities.","volume":"23","author":"Gunadi","year":"2023","journal-title":"BMC Public Health"},{"issue":"7","key":"yoi250004r39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41621","article-title":"The opioid epidemic: a review of the contributing factors, negative consequences, and best practices.","volume":"15","author":"Judd","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"yoi250004r40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/appi.ajp.2009.09081087","article-title":"The effect of inmate populations on estimates of DSM-IV alcohol and drug use disorders in the United States.","volume":"167","author":"Compton","year":"2010","journal-title":"Am J Psychiatry"},{"key":"yoi250004r14","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"yoi250004r5","unstructured":"National Academies of Sciences, Engineering, and Medicine. Adult Attention-Deficit\/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. National Academies Press; 2024."},{"key":"yoi250004r20","unstructured":"US Drug Enforcement Administration. Public safety alert: DEA issues warning about illegal online pharmacies. Accessed October 16, 2024. https:\/\/www.dea.gov\/alert\/dea-issues-warning-about-illegal-online-pharmacies"},{"key":"yoi250004r21","unstructured":"IQVIA. US national data: National Prescription Audit (NPA). https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/available-iqvia-data. Accessed April 10, 2024."},{"key":"yoi250004r22","unstructured":"Substance Abuse and Mental Health Services Administration. 2022 NSDUH detailed tables. Accessed April 10, 2024. https:\/\/www.samhsa.gov\/data\/report\/2022-nsduh-detailed-tables"},{"key":"yoi250004r23","unstructured":"Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health (NSDUH). Accessed April 26, 2023. https:\/\/www.samhsa.gov\/data\/data-we-collect\/nsduh-national-survey-drug-use-and-health"},{"key":"yoi250004r24","unstructured":"Substance Abuse and Mental Health Services Administration. NSDUH 2021 methodological resource book. 2022. Accessed May 11, 2024. https:\/\/www.samhsa.gov\/data\/report\/nsduh-2021-methodological-resource-book-mrb"},{"key":"yoi250004r25","unstructured":"Substance Abuse and Mental Health Services Administration. NSDUH 2022 methodological resource book. Accessed May 11, 2024. https:\/\/www.samhsa.gov\/data\/report\/nsduh-2022-methodological-resource-book-mrb"},{"key":"yoi250004r26","unstructured":"National Cancer Institute. Joinpoint trend analysis software, version 4.8.01. Accessed May 14, 2024. https:\/\/surveillance.cancer.gov\/joinpoint\/"},{"key":"yoi250004r30","unstructured":"Children and Adults With Attention-Deficit\/Hyperactivity Disorder. Telemedicine changes for ADHD following end of health emergency. Accessed June 21, 2024. https:\/\/chadd.org\/adhd-weekly\/telemedicine-changes-for-adhd-following-end-of-health-emergency\/"},{"key":"yoi250004r31","unstructured":"American Professional Society of ADHD and Related Disorders. The first U.S. guidelines for adult ADHD to be released by the American Professional Society of ADHD and Related Disorders. Accessed May 31, 2024. https:\/\/apsard.org\/wp-content\/uploads\/2022\/08\/APSARD-Adult-ADHD-Guidelines-Press-Release.pdf"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2831638\/jamapsychiatry_han_2025_oi_250004_1747773871.5104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:00:44Z","timestamp":1749034844000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2831638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0054","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}